Keratosis Clinical Trial
Official title:
Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis
Actinic keratosis (AK) is a skin condition that shows up on skin routinely exposed to the sun, such as the face, scalp, shoulders, chest, back, arms, and hands. The purpose of this study is to evaluate the safety of one, two, or three cycles of imiquimod for the treatment of AK. The AK lesions treated can be in adjacent and nonadjacent areas of the head, torso, and extremities. The total surface area for the AK lesions must be greater than 25 cm2. The secondary objective is to evaluate the effectiveness of treatment with imiquimod in people with large surface areas of AK.
This was a Phase 4, open-label, single-arm, multicenter study in male and female subjects
aged 18 years or older with clinically diagnosed AK lesions, conducted at 31 investigational
sites in the United States.
This study assessed the safety of imiquimod as a treatment for AK applied in doses ranging
from one packet 12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for
up to 3 cycles, depending upon treatment success and AK lesion recurrence. Eligible subjects
applied imiquimod 5% cream prior to normal sleeping hours 2 days per week to at least 4
clinically typical, visible, discrete, nonhypertrophic AK lesions in contiguous or
noncontiguous treatment areas totaling greater than 25 cm2 at baseline. Multiple treatment
areas could be exposed (i.e., head, torso and/or extremities), with the number of packets
determined by the investigator but not to exceed one packet for each 25 cm2 treatment area,
up to a maximum of 6 packets per dose. In each treatment cycle, dosing was to continue for
16 weeks (approximately 4 months), as instructed by the investigator, followed by a 2-month,
treatment-free follow-up period.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00239135 -
Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel
|
Phase 2 | |
Recruiting |
NCT06206681 -
Efficacy and Safety of Ultrapulse Carbon Dioxide Laser Treatment in Eyelid Tumors
|
||
Completed |
NCT00115154 -
Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands
|
Phase 4 | |
Recruiting |
NCT04336514 -
A Longitudinal Quantitative Assessment of the Effectiveness of Metatarsal Pads on Plantar Pressures
|
N/A | |
Recruiting |
NCT05942794 -
Identification of Oral Lesions Through an Autofluorescence System
|
N/A | |
Withdrawn |
NCT02851693 -
Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection
|
N/A | |
Withdrawn |
NCT02813902 -
A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
|
Phase 1 | |
Completed |
NCT00121511 -
The Effect of Efudex Treatment on Photoaged Skin
|
N/A | |
Completed |
NCT00114023 -
1-Year Follow up to the 1473-IMIQ Study
|
Phase 3 | |
Completed |
NCT05060237 -
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
|
Phase 1 | |
Recruiting |
NCT02737176 -
Tobacco Cessation Intervention Study for Oral Diseases
|
N/A | |
Completed |
NCT00110682 -
Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses
|
Phase 4 |